Disease-specific measure of quality of life for myasthenia gravis

Muscle and Nerve

Volumn 38, Issue 2, 2008, Pages 947-956

  Mullins, Larry L ^a   Carpentier, Melissa Y ^b   Paul, Robert H ^c   Sanders, Donald B ^d   McDermott, Michael ^e   Thornton, Charles ^e   Tawil, Rabi ^e   Barohn, Richard J ^e  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NONE

Author keywords

Myasthenia gravis; Physical ability; Quality of life

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOTHERAPY; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYASTHENIA GRAVIS; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SINGLE BLIND PROCEDURE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYASTHENIA GRAVIS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE;

EID: 49449087743     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21016     Document Type: Article

References (19)

1. Paul R, Cohen R, Gilchrist J, Aloia M, Goldstein J. Cognitive dysfunction in myasthenia gravis. J Neurol Sci 2000;179:59-64.
2. Paul R, Cohen R, Goldstein J, Gilchrist J. Fatigue and its impact on patients with myasthenia gravis. Muscle Nerve 2000;23:1402-1406.
3. Paul R, Cohen R, Gilchrist J, Zawacki T, Aloia M. What have we learned about cognitive function in myasthenia gravis: a review of methods and results. Neurosci Biobehav Rev 2001;25:75-81.
4. Pascuzzi RM. Myasthenia gravis and Lambert-Eaton syndrome. Ther Apher 2002;6:57-68.
5. Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001;22:363-369.
6. Padua L, Evoli A, Aprile I, Caliandro P, Batocchi A, Punzi C, et al, Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci 2002;23:59-68.
7. Mielenz T, Jackson E, Currey S, DeVellis R, Callahan LF. Psychometric properties of the Centers for Disease Control and Prevention Health-Related Quality of Life (CDC HRQOL) items in adults with arthritis. Health Qual Life Outcomes 2006;4:66.
8. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008 (in press).
9. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-772.
10. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
11. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-444.
12. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-139.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-483.
14. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
15. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968-1970.
16. Tindall RS. Immunointervention with cyclosporin A in autoimmune neurological disorders. J Autoimmun 1992;5:301-313.
17. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551.
18. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
19. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051-1057.